Balchem sold more and made more this quarter.
Revenue increased 11.2% to $284.0 million and diluted EPS rose 18.8% to $1.39, but the profit story is mostly volume and mix, not a margin breakout.
Gross profit climbed to $103.7 million, up 11.4%, yet gross margin barely moved, 36.4% to 36.5%, while operating margin nudged to 20.9% from 20.1%. That math matters because it shows the company needed more product flow, not a sudden pricing or cost win, to expand the bottom line.
Balchem points to one specific engine for the lift in the quarter.
"Earnings from Operations Three Months Ended June 30, Increase (Decrease) (in thousands) 2026 2025 % Change Human Nutrition & Health $ 42,381 $ 38,342 $ 4,039 10.5 % ... Earnings from operations $ 59,221 $ 51,442 $ 7,779 15.1 % % of net sales (operating margin) 20.9 % 20.1 % Human Nutrition & Health segment earnings from operations increased $4,039 primarily due to a gross margin contribution of $5,714."
Balchem / 10-Q / 2026-07-31
the Human Nutrition & Health business supplied the bulk of the incremental profit, and the company explicitly credits a gross-margin contribution from that segment for the improvement.
The filing also notes lower net interest expense.
"The decrease in net interest expense is primarily due to lower outstanding borrowings and lower interest rates."
Balchem / 10-Q / 2026-07-31
So lower interest costs and a 1.5% drop in diluted shares (32.7M to 32.2M) helped lift EPS beyond the operating-line gains.
Not all of the income move looks durable. Operating expenses for the six months rose 14.1% and compensation-related costs alone increased $8,069, which pushed operating expenses to 16.2% of sales from 15.6% a year earlier. At the same time, working capital inked a higher line: inventory is up 9.0% year over year and accounts receivable rose 9.6%. The company’s six-month operating cash flows grew only modestly, to $86.8 million from $83.7 million, as gains in net earnings were partly offset by working-capital changes.
Financing and investing flows also shifted: cash used in investing increased 37% and cash used in financing climbed 31% for the six-month comparison, leaving cash slightly lower at $63.2 million. Balchem does not explain the financing outflows in this filing; the 10-Q records the amounts but not a line-by-line cause.
Context: margins are near the company’s better recent levels. Balchem ran operating margins of 20.2% in 2025 after a steady climb from the mid-teens earlier in the decade.
The single clear next read is the company’s next 10-Q: will compensation-driven operating expenses and the working-capital build ease back, or will higher pay and receivables become a recurring drag on margin? That quarterly filing should show whether the mix-and-volume lift can keep covering rising costs.
Growth raised profits; rising compensation and working-capital levels could make those gains harder to sustain.
All figures from Balchem 10-Q for the quarter and six months ended June 30, 2026.